Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05849961 · ClinicalTrials.gov registry record
Exactech Hip Systems Post-Market Clinical Follow-up (PMCF)
A clinical trial of Hip Arthroplasty, Total, sponsored by Exactech.
- Recruiting
- Registry status
- 2,946
- Enrollment target
- 1
- Study location
NCT05849961: Recruiting study of Hip Arthroplasty, Total, sponsored by Exactech.
NCT05849961 is a study of Hip Arthroplasty, Total that is actively recruiting participants, run by Exactech. The registered enrollment target is 2,946 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05849961, a study of Hip Arthroplasty, Total, is actively recruiting participants, sponsored by Exactech.
- RECRUITING
- Registry status
- 2,946 participants
- Enrollment target
- 1
- Study location
Study Summary
A Post-Market Domestic (US) and International Data Collection to Assess Exactech Hip Systems
Primary Outcome
Harris Hip Score (HHS) - validated outcome score. Scores range from 0 (worse disability) to 100 (less disability). The HHS will be collected throughout the duration of the implanted device according to standard of care.
Conditions Studied
Interventions
- DEVICE Exactech Hip Systems
Study Locations (1)
Oklahoma
- Tulsa Bone & Joint Associates - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,946 participants |
| Start Date | 2023-10-13 |
| Est. Completion | 2036-12-31 |
What NCT05849961 shows while recruiting
NCT05849961 is an observational study that tracks outcomes without assigning an intervention. Its 2,946 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Hip Arthroplasty, Total appearing as the primary indexed condition, and to 1 intervention - of which Exactech Hip Systems is the first listed.
NCT05849961 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT05849961 about?
NCT05849961 is a clinical study titled "Exactech Hip Systems Post-Market Clinical Follow-up (PMCF)". A Post-Market Domestic (US) and International Data Collection to Assess Exactech Hip Systems
What is the current status of trial NCT05849961?
This trial is currently recruiting. The enrollment target is 2,946 participants. The study started on 2023-10-13. Estimated completion is 2036-12-31.
What conditions does trial NCT05849961 study?
This clinical trial studies the following conditions: Hip Arthroplasty, Total.
What interventions are being tested in trial NCT05849961?
The interventions under investigation include: Exactech Hip Systems (DEVICE).
Who is sponsoring clinical trial NCT05849961?
This trial is sponsored by Exactech, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05849961 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03331380 · 2,950 participants · NA
Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System
- NCT05564377 · 2,900 participants · Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- NCT07222995 · 2,900 participants · NA
Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs
- NCT05297734 · 2,996 participants · NA
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI